ASTH vs PFE

Astrana Health maintains its high-risk, high-reward profile, leveraging a rapidly expanding value-based care market with a clear strategic vision, particularly in Medicare Advantage and Medicaid. The company exhibits robust revenue growth (56% YoY in FY2025, 52.6% expected Q1 2026) and outperformance against its sector. Analyst consensus remains a 'Strong Buy' with significant upside. However, a m...

Pfizer Inc. remains a mature, large-cap pharmaceutical company with limited potential for the requested 10x growth within 3-5 years, which would require a market cap exceeding $1.4 trillion. While Q1 2026 results showed revenue of $14.45B and adjusted EPS of $0.75, both beating estimates, YoY revenue growth was modest at +5.4% and adjusted EPS declined -18%. Strategic legal wins for VYNDAQEL and C...